Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.44 |
| ▸ | NQO2 | P16083 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29461230 | 1.00 | MEN1 (0.55) | MEN1KMT2AHPGDHTR1AADRA1D | |
| Ethoxycarbonyl Group SCHEMBL28094498 | 0.83 | KMT2A (0.42) | MEN1KMT2AHPGDHTR1AADRA1D | |
| SCHEMBL24009064 | 0.82 | ALDH1A1 (0.58) | MEN1KMT2AHPGDEGFRALDH1A1 | |
| SCHEMBL73413 | 0.80 | SMN1; SMN2 (0.54) | MEN1KMT2AHPGDHTR1AADRA1D | |
| SCHEMBL17142295 | 0.80 | ALDH1A1 (0.45) | MEN1KMT2AHPGDALDH1A1MAPT | |
| SCHEMBL11583026 | 0.79 | HTR1A (0.50) | HPGDHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL3240985 | 0.79 | HTR1A (0.50) | MEN1KMT2AHPGDHTR1AADRA1D | |
| Hydrochloric Acid SCHEMBL28110846 | 0.79 | ALDH1A1 (0.44) | MEN1KMT2AHPGDALDH1A1MAPT | |
| SCHEMBL30605542 | 0.79 | PDE1B (0.54) | MEN1KMT2AHPGDALDH1A1MAPT | |
| SCHEMBL857052 | 0.79 | PDE1B (0.54) | MEN1KMT2AHPGDALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12404270-B2 | Quinazoline derivatives as LPA receptor 2 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-09-02 | — | — | US | disclosed |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | 1CBIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| CN-119677742-A | Novel external nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) inhibitor and application thereof | 斯拉瓦蒂人工智能科技私人有限公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20240352046-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2024-10-24 | — | — | US | disclosed |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | INVENTIVA (FR) | 2024-06-04 | — | — | US | disclosed |
| WO-2006032466-A2 | NEW BICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-30 | — | — | WO | disclosed |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1558585-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | Prana Biotechnology Ltd (AU) | 2005-08-03 | — | — | EP | disclosed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004031161-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| US-5373011-A | Substituted quinazoline fungicidal agents | AMERICAN CYANAMID COMPANY (US) | 1994-12-13 | — | — | US | disclosed |
| US-5270466-A | Substituted quinazoline fungicidal agents | AMERICAN CYANAMID COMPANY (US) | 1993-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | MEN1 3499/4885KMT2A 3902/4885HPGD 721/4885 |
| US-12404270-B2 | Quinazoline derivatives as LPA receptor 2 inhibitors | LPAR2, LPAR1, LPAR5 | MEN1 3828/4885KMT2A 1701/4885HPGD 1470/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | MEN1 2219/4885KMT2A 2821/4885HPGD 2770/4885 |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, NCEH1 | MEN1 4580/4885KMT2A 4508/4885HPGD 1027/4885 |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | YAP1, TEAD2, YES1 | MEN1 2269/4885KMT2A 1435/4885HPGD 1270/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | MEN1 3206/4885KMT2A 3326/4885HPGD 3372/4885 |
| US-20240352046-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | MEN1 2462/4885KMT2A 3970/4885HPGD 303/4885 |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | MEN1 3499/4885KMT2A 3902/4885HPGD 721/4885 |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | ENPP1, ENPP3, ENPP2 | MEN1 2462/4885KMT2A 3970/4885HPGD 303/4885 |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | MEN1 3438/4885KMT2A 3812/4885HPGD 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.